SCHEMBL2008562

SCHEMBL2008562

CCc1c(NCCN(C)C)cccc1S(=O)(=O)n1cc(C)c2cc(Cl)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.45
HTR6 P50406 11/20 0.39
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR7 P34969 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
DRD2 P14416 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
HRH1 P35367 1/20 0.38
ADRA1B P35368 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312410 0.83 HTR6 (0.36) HTR6HTR2AHTR7DRD2ALDH1A1
SCHEMBL2005725 0.76 KCNH2 (0.62) ACLYHTR6HTR2AHTR2CHTR7
SCHEMBL2314057 0.74 FABP4 (0.47) HTR6MEN1GAAKMT2ABRD4
SCHEMBL2317299 0.71 HTR6 (0.39) ACLYHTR6HTR2AHTR2CHTR7
SCHEMBL2005926 0.71 DRD2 (0.60) HTR6HTR2AHTR2CHTR7CYP3A4
SCHEMBL2008761 0.70 HTR6 (0.44) ACLYHTR6HTR2AHTR2CHTR7
SCHEMBL2002520 0.70 HTR6 (0.44) HTR6HTR7DRD2
SCHEMBL2006265 0.70 KCNH2 (0.48) HTR6HTR7CYP3A4CYP2D6DRD2
SCHEMBL2010180 0.69 HTR6 (0.56) HTR6HTR7DRD2
SCHEMBL12496662 0.67 ACLY (0.56) ACLYHTR6HTR2AHTR2CHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200980-B9 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION SUVEN LIFE SCIENCES LTD (IN) 2011-12-28 EP claimed
US-7964627-B2 Amino arylsulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-06-21 US claimed
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-26 US claimed
US-7964627-B2 Amino arylsulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR5A, HTR1A ACLY 3708/4885HTR6 1/4885HTR2A 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.